Advances in the Diagnosis and Treatment of Gastrointestinal Stromal Tumors
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Oncology".
Deadline for manuscript submissions: 18 July 2024 | Viewed by 245
Special Issue Editors
Interests: surgical oncology; gastrointestinal stromal tumors
Interests: medical oncology; gastrointestinal stromal tumors
Interests: surgical oncology; sarcoma; gastrointestinal stromal tumors; desmoid; melanoma; gastrointestinal cancer; digestive surgery
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
In recent decades, there have been several developments in biology of gastrointestinal stromal tumors (GIST) that enhance new diagnostic and therapeutic strategies. Surgery remains the cornerstone treatment in localized disease and can also be clinically relevant in the metastatic setting. However, the introduction of tyrosine kinase inhibitors (TKIs) was revolutionary in treating GIST patients, as it established treatment algorithms for patients with advanced GIST.
Novel therapeutic strategies focus on overcoming the heterogeneity of KIT or platelet-derived growth factor receptor (PDGFRA) secondary mutations and providing more potent inhibition of specific challenging mutations. Recently, new TKIs have been approved in patients harboring PDGFRA exon 18 D842V mutations. Additionally, there are several experimental therapies under investigation that could advance individualized patient care. Therapies based on the significant role of angiogenesis, immunology, and neural origin in the GIST biology could become a valuable enhancement of currently implemented treatment schemes. Generating miRNA networks that would predict miRNA regulatory functions is a promising approach that might help in better selection of potential biomarkers and therapeutical targets in GIST.
The correct combination and sequence of targeted agents and surgical procedures improves outcomes for patients with GIST and should be discussed individually within multidisciplinary expert teams.
In this Special Issue, we would like to invite original clinical and basic research, meta-analyses, and state-of-the-art reviews related to advances in the diagnosis and treatment of gastrointestinal stromal tumors.
We will be grateful to receive your submissions.
Dr. Dimitrios Balalis
Dr. Stefania Kokkali
Prof. Dr. Nikolaos Vassos
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- GIST
- surgery
- mutation
- targeted agent
- tyrosine kinase inhibitor
- biomarker
